Effect of leptin on n-methyl-n'-niro-n-nirosoguanidine induced histological and genetic changes in stomach of male sprague-dawley rats

• Main Author: Faizatul Isyraqiah Ahmad Muhammad (Author)
• Format: Thesis Book
• Language: English
• Published: Sungai Buloh, Selangor Universiti Teknologi MARA. Faculty of Medicine 2019
• Subjects: Leptin > adverse effects; Adipokines > adverse effects
• Online Access: Click Here to View Status and Holdings.
• Item Description: UiTM Digitized
• Physical Description: xix, 249 pages illustrations, charts (some colour) 30 cm 1 computer optical disc (4 ¾ in.)
• Format: System requirements for CD-ROM: Intel Pentium II or faster processor with 450 MHz (or equivalent), browser Internet Explorer 5.5 or higher (6.0 or higher recommended), Firefox 1.0.2 or higher, Acrobat
• Bibliography: Includes bibliographical references (page 175-236)

Obese individuals are at a higher risk of developing gastric cancer. Whether this is related to the higher serum leptin levels in obese individuals is uncertain but leptin has been shown to promote the proliferation of gastric cancer cell in vitro. Its impact on tumour formation in vivo has not been examined. This study therefore examined the effect of leptin in a rat model of N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) induced gastric adenocarcinoma. Six-week old male Sprague-Dawley rats were divided into 4 groups (n-8). Group 1 served as controls. Group 2 was given 24 mg/kg/day of MNNG in drinking water. Group 3 was given intraperitoneal injection of 60 µg/kg/day of leptin. Group 4 was treated with both MNNG and leptin. Body weight and water intake were measured weekly. Rats were euthanized after 40 weeks and stomachs were collected for histopathological examination, microarray, and RT qPCR. Data were analysed using one-way ANOVA and Fisher's exact test. Gastric hyperplasia was observed in 50 % of MNNG-treated stomachs (p<0.05), with no significant changes in gene expression. Compared to control, 25% of LEPT-treated stomachs showed hyperplasia and dysplasia, and upregulated genes include Furin (protein maturation), Eeflal and Eif4g2 (translation factors), Tmed2 (vesicular trafficking), Rab7a (plasma membrane trafficking), Rfwd2 (protein degradation), Fth1 and Fill (oxygen transport), Tspan8, Tspan1, Fxyd3, and Rack! (cell migration), Pde4d (signal transduction), Nuprl and Ybx/ (transcription factors), Ptma and Tmem134 (oncogenes), Srsf2 (mRNA maturation), and Reep5 (cell proliferation). MNNG + LEPT-treated rats showed gastric changes including hyperplasia, dysplasia, hypertrophy, and adenocarcinoma (p<0.01) in 75% of the rats. Genes upregulated include microRNAs, olfactory receptors, transcription factor (Hey2), vesicular trafficking (Tmed2), and cell proliferation (Len11). Lungs of LEPT-treated rats (25%) and MNNG + LEPT-treated rats (50%) showed presence of lung adenocarcinoma. No tumours were found in the lungs of control and MNNG-treated rats. There was no evidence of tumours in the livers of all rats. No significant differences were evident in body weight and water intake between the groups. It appears that leptin administration induced significant changes in carcinogenic genes and microscopic changes in stomach. of rats, and its combined treatment with MNNG further enhances gastric carcinogenesis. These findings suggest leptin's role as an inducing and contributing factor towards the increased prevalence of gastric cancer amongst obese people